Philips Lifts Outlook on Better Supply Chains, Restructuring

(Bloomberg) — Royal Philips NV raised its sales forecast for the year following better supply of parts and a restructure that slashed thousands of jobs while still working through a costly device recall.

Revenue should rise by a mid single-digit percentage, compared with previous guidance for low single-digit growth, the Dutch medical-equipment maker said Monday. Second-quarter adjusted earnings before interest, taxes and amortization rose to €453 million ($504 million), beating the average estimate of €389 million in a Bloomberg survey of analysts.

Philips is making good progress on planned improvements, including enhancing patient safety and quality, Chief Executive Officer Roy Jakobs, who took the company’s reins in October and started his tenure by cutting 10,000 jobs, said in a statement.

Working through the recall of breathing devices for sleep apnea remains the biggest priority, he said.  

The company has set aside around €1 billion for a recall of around 5.5 million devices globally and booked additional provisions of €575 million as part of a planned settlement in the US to compensate patients. Philips is a defendant in several class-action lawsuits and individual personal injury claims in the US as consumers claim its machines use foam that can degrade and be ingested, possibly presenting a cancer risk. 

Philips shares are up 55% so far this year.

Still, the stock is under pressure as it slid as much as 74% after the firm initiated its first recall of potentially faulty sleep apnea products in June 2021. The US Food & Drug Administration labeled it as a Class 1 issue — the most serious type.

Philips is also being investigated by the US Department of Justice and remains in ongoing discussions with the FDA regarding a proposed consent decree.

The company has not yet made any provisions for these matters.

The company also raised its full-year outlook for Ebita margin to the upper end of the high-single-digit range from high single-digit adjusted operating profit margin earlier. The raised expectations exclude impacts from the recall beyond Philips’ current assumptions, it said.

Revenue to rose 9% to €4.5 billion in the second quarter.

Comparable order intake declined 8% in the period on high base even as order book continued to grow.

(Updates with details from the statement)

More stories like this are available on bloomberg.com

©2023 Bloomberg L. P.